What is EWTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.94B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for EWTX?

P/E (TTM) is n/a and 52-week range is $14.25 to $48.51 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s EWTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for EWTX?

The company profile lists net income (TTM) near $-199M, EPS (TTM) near $-1.85 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Edgewise Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boulder, Colorado, US, 107.6M shares outstanding, ISIN US28036F1057 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Edgewise Therapeutics Inc

$EWTX

Health Care · Pharmaceuticals

IR Run Scenarios

$36.28

-5.64%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 146 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

Employees

146

Website

edgewisetx.com/

IPO

2021-03-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)